TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.

Autoria(s): Bonnefoi, H.; Piccart, M.; Bogaerts, J.; Mauriac, L.; Fumoleau, P.; Brain, E.; Petit, T.; Rouanet, P.; Jassem, J.; Blot, E.; Zaman, K.; Cufer, T.; Lortholary, A.; Lidbrink, E.; André, S.; Litière, S.; Lago, L.D.; Becette, V.; Cameron, D.A.; Bergh, J.; Iggo, R.; EORTC 10994/BIG 1-00 Study Investigators
Data(s)

2011
Identificador

https://serval.unil.ch/notice/serval:BIB_EC7CF00354A2

info:pmid:21570352

https://serval.unil.ch/resource/serval:BIB_EC7CF00354A2.P001/REF

http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_EC7CF00354A27

urn:nbn:ch:serval-BIB_EC7CF00354A27
Idioma(s)

eng
Fonte

Lancet Oncology126527-539
Palavras-Chave #Adult; Aged; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Breast Neoplasms/chemistry; Breast Neoplasms/drug therapy; Female; Humans; Middle Aged; Mutation; Neoadjuvant Therapy; Receptor, erbB-2/analysis; Receptors, Estrogen/analysis; Taxoids/administration & dosage; Taxoids/therapeutic use; Tumor Suppressor Protein p53/genetics; Tumor Suppressor Protein p53/physiology
Tipo

info:eu-repo/semantics/article

article
Contribuinte(s)

EORTC 10994/BIG 1-00 Study Investigators
Formato

application/pdf
Direitos

info:eu-repo/semantics/openAccess

Copying allowed only for non-profit organizations

https://serval.unil.ch/disclaimer
Acesso ao item digital